Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.84 | 0.87 | -0.88 | 6.76 |
| FCF Yield | -0.14% | 0.18% | -2.12% | -3.57% |
| EV / EBITDA | -169.79 | -94.49 | -31.70 | -30.63 |
| Quality | ||||
| ROIC | -4.06% | -9.87% | -27.94% | -23.73% |
| Gross Margin | 85.62% | 83.02% | 83.73% | 83.40% |
| Cash Conversion Ratio | 0.03 | -0.24 | 0.48 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 29.41% | 29.38% | 28.16% | 56.62% |
| Free Cash Flow Growth | -201.54% | 106.84% | 14.59% | -4.78% |
| Safety | ||||
| Net Debt / EBITDA | -1.84 | -1.91 | -0.49 | -0.27 |
| Interest Coverage | -1.25 | -2.33 | -5.03 | -4.95 |
| Efficiency | ||||
| Inventory Turnover | 4.12 | 3.48 | 1.31 | 1.62 |
| Cash Conversion Cycle | 54.62 | 104.98 | 150.46 | 119.54 |